What is erysipelas?
Erysipelas affects the upper dermis and extends into the superficial cutaneous lymphatics. It is also known as St. Anthony's fire, with reference to the intense rash associated with it.
Who gets erysipelas?
Erysipelas most often affects infants and the elderly, but can affect any age group. Risk factors are similar to those for other forms of cellulitis. They may include:
- Previous episode(s) of erysipelas
- Breaks in the skin barrier due insect bites, ulcers and chronic skin conditions such as psoriasis, athlete’s foot and eczema
- Current or prior injury (eg trauma, surgical wounds, radiotherapy)
- In newborns, exposure of the umblical cord and vaccination site injury
- Nasopharyngeal infection
- Venous disease (eg gravitational eczema, leg ulceration) and/or lymphoedema
- Immune deficiency or compromise, such as
- Nephrotic syndrome
What causes erysipelas?
Unlike cellulitis, almost all erysipelas is caused by Group A beta haemolytic streptococci (Streptococcus pyogenes). Staphylococcus aureus, including methicillin resistant strains (MRSA),Streptococcus pneumoniae,Klebsiella pneumoniae,Yersinia enterocolitica, andHaemophilus influenzae have also been found to cause erysipelas.
What are the clinical features of erysipelas?
Symptoms and signs of erysipelas are usually abrupt in onset and often accompanied by fevers, chills and shivering.
Erysipelas predominantly affects the skin of the lower limbs, but when it involves the face it can have a characteristic butterfly distribution on the cheeks and across the bridge of the nose.
- The affected skin has a very sharp, raised border.
- It is bright red, firm and swollen. It may be finely dimpled (like an orange skin).
- It may be blistered, and in severe cases may become necrotic.
- Bleeding into the skin may cause purpura.
- Cellulitis does not usually exhibit such marked swelling, but shares other features with erysipelas, such as pain and increased warmth of affected skin.
- In infants, it often occurs in the umbilicus or diaper/napkin region.
- Bullous erysipelas can be due to co-infection with Staphylococcus aureus (including MRSA).
What are the complications of erysipelas?
Erysipelas recurs in up to one third of patients due to:
- Persistence of risk factors
- Lymphatic damage (hence impaired drainage of toxins)
Complications are rare but can include:
- Chronic leg swelling
- Infections distant to the site of erysipelas:
- Infective endocarditis (heart valves)
- Septic arthritis
- Post-streptococcal glomerulonephritis (a kidney condition affecting children)
- Cavernous sinus thrombosis (dangerous blood clots that can spread to the brain)
- Streptococcal toxic shock syndrome (rare)
How is erysipelas diagnosed?
Erysipelas is usually diagnosed by the characteristic rash. There is often a history of a relevant injury. Tests may reveal:
- Raised white cell count
- Raised C-reactive protein
- Positive blood culture identifying the organism
MRI and CT are undertaken in case of deep infection.
What is the treatment for erysipelas?
- Cold packs and analgesics to relieve local discomfort
- Elevation of an infected limb to reduce local swelling
- Compression stockings
- Wound care with saline dressings that are frequently changed
- Oral or intravenous penicillin is the antibiotic of first choice.
- Erythromycin, roxithromycin or pristinamycin may be used in patients with penicillin allergy.
- Vancomycin is used for facial erysipelas caused by MRSA
- Treatment is usually for 10–14 days
What is the outlook for erysipelas?
While signs of general illness resolve within a day or two, the skin changes may take some weeks to resolve completely. No scarring occurs.
Long term preventive treatment with penicillin is often required for recurrent attacks of erysipelas.
Erysipelas recurs in up to one third of patients due to persistence of risk factors and also because erysipelas itself can cause lymphatic damage (hence impaired drainage of toxins) in involved skin which predisposes to further attacks.
If patients have recurrent attacks, long term preventive treatment with penicillin may be considered.
- Celestin, Ruth, et al. Erysipelas: a common potentially dangerous infection. Acta dermatovenerologica Alpina, Pannonica, et Adriatica 16.3 (2007): 123-127 PDF file
- Morris AD. Cellulitis and erysipelas. BMJ Clinical Evidence. 2008;2008:1708..
- Sjöblom AC, Eriksson B, Jorup-Ronstrom C, et al. Antibiotic prophylaxis in recurrent erysipelas. Infection 1993;21:390–393. [PubMed]
- Erysipelas – Merck Manual Professional version.
- Edwards, J., Green, P., & Haase, D. (2006). A blistering disease: bullous erysipelas. Canadian Medical Association Journal, 175(3), 244-244.